BioSyent Past Earnings Performance
Past criteria checks 3/6
BioSyent has been growing earnings at an average annual rate of 5.1%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 8.2% per year. BioSyent's return on equity is 18.6%, and it has net margins of 20.4%.
Key information
5.1%
Earnings growth rate
9.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 8.2% |
| Return on equity | 18.6% |
| Net Margin | 20.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Revenue & Expenses BreakdownBeta
How BioSyent makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 32 | 6 | 18 | 0 |
| 30 Sep 23 | 31 | 6 | 18 | 0 |
| 30 Jun 23 | 29 | 5 | 17 | 0 |
| 31 Mar 23 | 27 | 5 | 16 | 0 |
| 31 Dec 22 | 28 | 5 | 16 | 0 |
| 30 Sep 22 | 28 | 6 | 15 | 0 |
| 30 Jun 22 | 28 | 6 | 14 | 0 |
| 31 Mar 22 | 28 | 6 | 14 | 0 |
| 31 Dec 21 | 29 | 6 | 14 | 0 |
| 30 Sep 21 | 27 | 5 | 14 | 0 |
| 30 Jun 21 | 26 | 4 | 15 | 0 |
| 31 Mar 21 | 24 | 4 | 13 | 0 |
| 31 Dec 20 | 22 | 4 | 12 | 0 |
| 30 Sep 20 | 22 | 4 | 11 | 0 |
| 30 Jun 20 | 23 | 5 | 11 | 0 |
| 31 Mar 20 | 23 | 5 | 11 | 0 |
| 31 Dec 19 | 21 | 4 | 10 | 0 |
| 30 Sep 19 | 22 | 5 | 10 | 0 |
| 30 Jun 19 | 21 | 5 | 10 | 0 |
| 31 Mar 19 | 22 | 6 | 10 | 0 |
| 31 Dec 18 | 22 | 6 | 10 | 0 |
| 30 Sep 18 | 22 | 5 | 10 | 0 |
| 30 Jun 18 | 22 | 6 | 10 | 0 |
| 31 Mar 18 | 21 | 5 | 10 | 0 |
| 31 Dec 17 | 21 | 5 | 10 | 0 |
| 30 Sep 17 | 20 | 5 | 9 | 0 |
| 30 Jun 17 | 19 | 5 | 9 | 0 |
| 31 Mar 17 | 18 | 4 | 8 | 0 |
| 31 Dec 16 | 18 | 4 | 8 | 0 |
| 30 Sep 16 | 17 | 4 | 8 | 0 |
| 30 Jun 16 | 17 | 4 | 8 | 0 |
| 31 Mar 16 | 16 | 4 | 8 | 0 |
| 31 Dec 15 | 15 | 4 | 7 | 0 |
| 30 Sep 15 | 15 | 4 | 6 | 0 |
| 30 Jun 15 | 14 | 4 | 6 | 0 |
| 31 Mar 15 | 13 | 4 | 5 | 0 |
| 31 Dec 14 | 12 | 3 | 5 | 0 |
| 30 Sep 14 | 11 | 3 | 5 | 0 |
| 30 Jun 14 | 10 | 3 | 5 | 0 |
| 31 Mar 14 | 9 | 2 | 4 | 0 |
| 31 Dec 13 | 8 | 2 | 4 | 0 |
| 30 Sep 13 | 7 | 2 | 3 | 0 |
| 30 Jun 13 | 6 | 2 | 3 | 0 |
Quality Earnings: RX has a high level of non-cash earnings.
Growing Profit Margin: RX's current net profit margins (20.4%) are higher than last year (19.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RX's earnings have grown by 5.1% per year over the past 5 years.
Accelerating Growth: RX's earnings growth over the past year (18.4%) exceeds its 5-year average (5.1% per year).
Earnings vs Industry: RX earnings growth over the past year (18.4%) did not outperform the Pharmaceuticals industry 22%.
Return on Equity
High ROE: RX's Return on Equity (18.6%) is considered low.